Determination of overall survival, disease-free period in patients diagnosed with gastric cancer.

Keywords

GASTRIC NEOPLASMS, MORTALITY, ANALYSIS OF SURVIVAL, SURVIVAL WITHOUT DISEASE

How to Cite

Calvache Guamán, J., Calderón Robalino, D., Jara Almeida, M., Muñoz Bermeo, R., & Ontaneda Luciano, M. (2017). Determination of overall survival, disease-free period in patients diagnosed with gastric cancer. Oncology Journal (Ecuador), 27(1), 74–83. Retrieved from https://roe.solca.med.ec/index.php/johs/article/view/28

Abstract

Introduction: In the treatment of gastric cancer there is an active debate on whether the use of adjuvant chemotherapy provides greater survival compared to gastrectomy surgery. The present study identifies the disease-free period in patients with gastric cancer in clinical stages IB, II, IIIA, IIIB and VAT treated with McDonald protocol versus surgery alone.

Methods: The present retrospective longitudinal study was performed in patients with gastric cancer treated in Solca-Quito in the period 2002 to 2007. Survival in the groups was determined using Kaplan Meier.

Results: There were 67 patients in each group. With stage IB, 6 cases with MacDonald protocol had a survival of 129 weeks VS 18 cases with surgery, 173.9 weeks (P = 0.34). In stage II, 18 cases with MacDonald protocol, survival of 132.5 weeks VS 7 cases with surgery, 173.9 weeks (P = 0.053). In stage IIIA, 20 cases with MacDonald protocol, survival of 115.4 weeks VS 16 cases with surgery, 85.9 weeks (P = 0.31). In stage IIIB, 10 cases with MacDonald protocol, survival of 88.2 weeks VS 9 cases with surgery, 81.6 weeks (P = 0.84). In stage IVA, 13 cases with MacDonald protocol, survival of 104.9 weeks VS 17 cases with surgery, 52.6 weeks (P = 0.079).

Conclusions: In the present study there were no statistical differences between the survival of patients with gastric cancer who underwent surgery with gastrectomy versus patients who underwent adjuvant chemotherapy.

Downloads

Download data is not yet available.